Indaptus Therapeutics

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Indaptus Therapeutics is advancing the Decoy bacteria triggered immune response technology for cancer and viral indications.

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

Shares of INDP stock are skyrocketing on Wednesday after the U.S. Patent and Trademark Office made a big move for Indaptus Therapeutics. The post INDP Stock: The Patent News That Has Indaptus Therapeutics Skyrocketing Today appeared first on InvestorPlace.

INDP Stock: The Patent News That Has Indaptus Therapeutics Skyrocketing Today

Shares of Indaptus Therapeutics Inc. INDP, +190.95% nearly tripled on massive volume in midday trading, to bounce off the previous session's record closing low, after the developer of treatments for hepatitis and HIV announced the allowance of a patent for its platform technology. The stock was up as much as 307.8% at a six-month high of $28.83 before paring gains to be up 184.3%.

Indaptus Therapeutics stock nearly triples on heavy volume after allowance for patent of platform technology

The United States Patent and Trademark Office has issued a notice of patent allowance to Indaptus Therapeutics Inc's (NASDAQ: INDP) platform technology. The patent provides broad protection for applying the Company's platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.

Why Are Indaptus Therapeutics Shares Shooting Higher On Wednesday?

The stock price of Indaptus Therapeutics Inc (NASDAQ: INDP) is trading at over 57% pre-market today. This is why it happened.

INDP Stock: Why It Significantly Increased Today

Key Patent for Platform Technology to Treat or Inhibit HBV and HIV Infections Key Patent for Platform Technology to Treat or Inhibit HBV and HIV Infections

Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent

Intec Parent

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company," and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ("Decoy") and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company's therapeutic focus.

Intec Closes Merger with Decoy Biosystems

News for Indaptus Therapeutics Stock (INDP)